Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
PARSIPPANY, N.J., May 01, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the following two healthcare conferences:
- Deutsche Bank 43rd Annual Health Care Conference in Boston, on Wednesday, May 9 at 2:10 PM ET
- Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, on Tuesday, May 15, at 1:40 PM PT (4:40PM ET)
A live audio webcast of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcasts will be archived on the Pacira website for two weeks following the presentation dates.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Christian Pedetti (973) 254-4387 [email protected]
